TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19398935
Drug: (32)P‐CP injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: (32)P‐CP injection
Study: 16416607
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied to one surgical wound
Study: 16416607
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied to the second surgical wound (Control)
Study: 10593714
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) formulations of rifampicin, isoniazid and pyrazinamide
Study: 10593714
Drug: Separate formulations
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate formulations of rifampicin, isoniazid and pyrazinamide
Study: 1750473
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ampicillin‐sulbactam and indomethacin
Study: 20089221
Drug: N-acetylcysteine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine, 600 mg every 12 h intravenously
Study: 11933280
Drug: Pegasus Cairwave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegasus Cairwave Therapy System in conjunction with the Proactive 2 Seating cushion (Group B)
Study: 8895286
Drug: Variable-dose PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable-dose PCA (VDPCA) - 0.5, 1.0, and 1.5 mg boluses of morphine
Study: 8895286
Drug: Fixed-dose PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose PCA (FDPCA) - 1.0 mg of morphine
Study: 2070384
Drug: Duraphat varnish
Normalized name: testosterone enanthate Injectable Solution [Durathate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraphat varnish treatments 3 times a week, once a year
Study: 2070384
Drug: Duraphat varnish
Normalized name: testosterone enanthate Injectable Solution [Durathate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraphat varnish treatments every 6 months
Study: 31128770
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum uromodulin (sUMOD) levels (mean sUMOD level was 127±64ng/mL)
Study: 31261494
Drug: Eteplirsen 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eteplirsen 30 or 50 mg/kg
Study: 28100282
Drug: Single-strength group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-strength group (SS, SMX/TMP of 400/80 mg daily)
Study: 28100282
Drug: Half-strength group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-strength group (HS, SMX/TMP of 200/40 mg daily)
Study: 28100282
Drug: Escalation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation group (ES, started with 40/8 mg daily, increasing to 200/40 mg daily)
Study: 26470637
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (1600 mg) and vitamin D3 (1000 IU) ingested prior to cycling for 5 months
Study: 21242642
Drug: Simvastatin (SIM)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (SIM) in combination with Losartan (LOS)
Study: 18428069
Drug: Tai-Kang-Ning (TKN)
Normalized name: Scrophularia ningpoensis root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai-Kang-Ning (TKN) capsule
Study: 16611950
Drug: Telithromycin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (800 mg daily for 10 days)
Study: 12962869
Drug: Tacrolimus (Tac)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (Tac) with mycophenolate mofetil (MMF) and steroids
Study: 10849040
Drug: L-5-hydroxytryptophan (5-HTP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (5-HTP), 300 mg per day
Study: 9322355
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (10 mg/m2 i.v. day 1), Vinblastine (5 mg/m2 i.v. day 1 and 15), Amifostine (910 mg/m2 in short i.v. infusion prior to MMC)
Study: 29198060
Drug: MDMA administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDMA administration
Study: 1446958
Drug: Indolidan (IN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indolidan (IN) administered i.v. at 1,180 +/- 340 micrograms (15 micrograms/kg) over two hours
Study: 1446958
Drug: Indolidan (IN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indolidan (IN) administered p.o. at 231 +/- 44 micrograms
Study: 22846396
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg dose of H1N1 vaccine
Study: 22846396
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination with licensed trivalent seasonal influenza vaccine
Study: 24961747
Drug: H1N1 vaccine
Normalized name: Influenza H1N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1N1 vaccine
Study: 12914507
Drug: Ciprofloxacin (0.3%)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (0.3%) eardrops, 5 drops twice daily for 9 days
Study: 12914507
Drug: Framycetin (0.5%),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Framycetin (0.5%), gramicidin, dexamethasone (FGD) eardrops, 5 drops twice daily for 9 days
Study: 10503681
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (800 microg) and nebulized salbutamol (0.15 mg/kg)
Study: 10503681
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (2 mg/kg) and nebulized salbutamol (0.15 mg/kg)
Study: 7191832
Drug: Low concentrated
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentrated amino acid‐carbohydrate solution (PE 900 with 25 g x 1(‐1) amino acids and 50 g x 1(‐1) Polyols)
Study: 7191832
Drug: Low concentrated
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentrated amino acid‐carbohydrate solution (PE 900)
Study: 28196279
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received the same conventional dysphagia therapy without HLE.
Study: 9291414
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium cromoglycate
Study: 2872794
Drug: Hyaluronidase therapy
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase therapy (500 National Formulary units/kg intravenously every 6 hours for 48 hours)
Study: 2872794
Drug: Hyaluronidase therapy
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase therapy
Study: 20660140
Drug: Experimental meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental meningococcal serogroup B vaccine (five formulations, n = 25 in each group)
Study: 20660140
Drug: Experimental meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental meningococcal serogroup B vaccine
Study: 12196053
Drug: loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine 10 mg/d
Study: 12196053
Drug: chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorpheniramine maleate 12 mg twice daily
Study: 9527356
Drug: Mouthrinse solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthrinse solution containing 0.025% NaF
Study: 9527356
Drug: Tablet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing 0.55 mg NaF
Study: 7837388
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen (four courses of doxorubicin followed by eight courses of CMF)
Study: 694481
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d tamoxifen by mouth
Study: 31722650
Drug: Integrative cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative cognitive-behavioral therapy (25 ± 3 sessions)
Study: 28317510
Drug: 12-step facilitation
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-step facilitation (TSF) intervention: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12)
Study: 21869685
Drug: Ramelteon 8
Normalized name: ramelteon 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon 8 mg/d
Study: 19628206
Drug: 600 microg
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 microg of sublingual misoprostol
Study: 19628206
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg of sublingual misoprostol
Study: 19628206
Drug: Intravenous methylergometrine
Normalized name: methylergometrine
DrugBank: Methylergometrine (DB00353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylergometrine
Study: 11678862
Drug: Montelukast (MT)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (MT) 10 mg once a day
Study: 11678862
Drug: Cetirizine (CET)
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine (CET) 10 mg once a day
Study: 9759273
Drug: Subcutaneous epinephrine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epinephrine, 10 micrograms/kg (n = 28)
Study: 9759273
Drug: Subcutaneous terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline, 10 micrograms/kg (n = 26)
Study: 2894359
Drug: Fenoldopam (DA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (DA1 receptor agonist)
Study: 20600478
Drug: AS03(B)-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(B)-adjuvanted vaccine (1.9microg HA)
Study: 20600478
Drug: AS03(A)-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted vaccine (3.75microg HA)
Study: 18975322
Drug: R788 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: R788 100 mg
Study: 18975322
Drug: R788 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: R788 150 mg
Study: 18975322
Drug: R788 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: R788 50 mg
Study: 16021197
Drug: Systemic medications
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic medications (acetazolamide +/- mannitol)
Study: 11351768
Drug: Aspirin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (25 mg b.d.)
Study: 11351768
Drug: Dipyridamole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (400 mg b.d.)
Study: 9197296
Drug: Alfentanil by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil by computer-controlled infusion
Study: 9197296
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg) plus Alfentanil
Study: 19092246
Drug: Midazolam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (4 mg)
Study: 3916837
Drug: Ketanserin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (60 mg daily for the first month, 120 mg daily for the second and third months)
Study: 25749495
Drug: Non-respiratory physiotherapist
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-respiratory physiotherapist treatments
Study: 25749495
Drug: Respiratory physiotherapist
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory physiotherapist treatments
Study: 1762975
Drug: Dry sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry sterile gauze dressing (DSGD) changed daily
Study: 24885844
Drug: No-treatment (wait
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment (wait list) control condition
Study: 22403699
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody (mAb) immunotherapy
Study: 22403699
Drug: Vaccine subgroup
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine subgroup
Study: 22403699
Drug: Cytokine immunotherapy
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine immunotherapy
Study: 15969642
Drug: 2% dorzolamide/0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% dorzolamide/0.5% timolol combination eye drops twice daily
Study: 15969642
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost eye drops once daily
Study: 10385131
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate gel forming solution 0.5% (Timoptic‐XE)
Study: 6304203
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg/m2 per day for two weeks)
Study: 28408059
Drug: BCAAs +
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAAs + HPHF diet (1.2g/kg protein, 30g fiber, 110g BCAAs daily)
Study: 27035404
Drug: L-methylfolate calcium
Normalized name: L-Methylfolate Calcium
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-methylfolate calcium 15 mg
Study: 22404241
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (it‐M) 0.1 mg
Study: 22404241
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (it‐M)
Study: 15538055
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI with thrombolytic therapy plus glycoprotein IIb/IIIa inhibitor
Study: 15538055
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI with glycoprotein IIb/IIIa inhibitor alone
Study: 15538055
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI with thrombolytic therapy
Study: 10365803
Drug: Ribavirin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (800 mg/day) plus leucocytic interferon-alpha (3 mega units thrice weekly)
Study: 10365803
Drug: Interferon-alpha alone
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha alone (3 mega units thrice weekly)
Study: 1851191
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (6 mg)
Study: 7012996
Drug: Bacampicillin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin (800 mg twice a day)
Study: 7012996
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg three times a day)
Study: 24214585
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole (initial dose 40 mg, then 40 mg every 12 hours for 3 days, followed by 40 mg orally)
Study: 24214585
Drug: Intravenous ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ranitidine (initial dose 50 mg, then every 8 hours for 3 days, followed by 150 mg every 12 hours)
Study: 15534928
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole
Study: 20631407
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg dietary phosphorus diet
Study: 20631407
Drug: lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: lanthanum carbonate 1000 mg three times daily
Study: 20631407
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg dietary phosphorus diet plus placebo
Study: 20095352
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy history (C group, n = 52)
Study: 20095352
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative chemotherapy history (N group, n = 55)
Study: 10945316
Drug: Transdermal mecamylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal mecamylamine 6 mg/24 h
Study: 8454793
Drug: N/A (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: N/A (control group with no injections)
Study: 27382674
Drug: Dermatophagoides farina
Normalized name: Dermatophagoides farinae
DrugBank: Dermatophagoides farinae (DB10400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatophagoides farina extracts sublingual immunotherapy for 2 years
Study: 26237978
Drug: Acupuncture +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture + NSES (Combined treatment)
Study: 21803113
Drug: Rivastigmine 0
Normalized name: rivastigmine 0.192 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 0 mg (placebo)
Study: 18377124
Drug: Individual cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive‐behavioral therapy (ICBT)
Study: 9404178
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural block with 0.25% bupivacaine 1 ml.kg‐1 and preservative‐free ketamine 0.5 mg.kg‐1
Study: 9404178
Drug: Ilioinguinal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal nerve block with 0.25% bupivacaine 0.5 ml.kg‐1 and infiltration of the wound with 0.25% bupivacaine 0.5 ml.kg‐1
Study: 1053479
Drug: Furosemide (loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (loop diuretic)
Study: 1053479
Drug: Potassium-sparing diuretic
Normalized name: Potassium-sparing diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing diuretic added to thiazide or furosemide
Study: 1053479
Drug: Diuretics in
Normalized name: OTHER DIURETICS in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics in diuretic doses
Study: 1053479
Drug: Furosemide or
Normalized name: furosemide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide or increased dose of loop diuretic
Study: 22401279
Drug: hCG (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG (3000 IU intramuscular injection on day 5 after oestrus)
Study: 22401279
Drug: Saline (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (intramuscular injection on day 5 after oestrus)
Study: 18001713
Drug: Mucuna pruriens
Normalized name: Mucuna Pruriens Seed
DrugBank: Mucuna pruriens seed (DB14299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucuna pruriens treatment
Study: 16511633
Drug: Closed Tracheal
Normalized name: bovine type II collagen (tracheal cartilage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed Tracheal Suction System (CTSS) without daily change
Study: 11127843
Drug: Beta-receptor antagonists
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-receptor antagonists (short term use <6 weeks)
Study: 11127843
Drug: Nifedipine (concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (concurrent with MgSO4)
Study: 9257783
Drug: Short-term immunotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens from grass and rye pollen (n = 41)
Study: 9257783
Drug: Short-term immunotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens from grass and rye pollen (n = 22)
Study: 3304473
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP regimen (low doses of adriamycin)
Study: 3304473
Drug: Chemotherapy, radiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, radiotherapy, splenectomy, leukapheresis, monoclonal antibodies, immunomodulating agents
Study: 31628854
Drug: Ubrogepant 400
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubrogepant 400 mg
Study: 29120908
Drug: Thiopurine treatment
Normalized name: thiotaurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopurine treatment (discontinuation rate 22% in accepting group)
Study: 29120908
Drug: Thiopurine treatment
Normalized name: thiotaurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopurine treatment (steady-state metabolite levels)
Study: 22385415
Drug: Diclofenac-tramadol combination
Normalized name: diclofenac, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-tramadol combination (diclofenac 100 mg rectal suppository 8 hourly till 24 h + tramadol 75 mg intravenous 6 hourly)
Study: 22385415
Drug: Diclofenac-acetaminophen combination
Normalized name: acetaminophen / diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-acetaminophen combination (diclofenac 100 mg rectal suppository 8 hourly till 24 h + acetaminophen 1 g intravenous 6 hourly)
Study: 22385415
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (diclofenac-tramadol and diclofenac-acetaminophen)
Study: 10378323
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (200 IU dalteparin per kilogram body-weight per 24 hours), firm compression bandages, and encouraged walking
Study: 8927235
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) 100 micrograms
Study: 8354332
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (5 g)
Study: 8354332
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (15 g)
Study: 8354332
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (30 g)